Last updated: February 20, 2026
What is DURAQUIN?
DURAQUIN (hydroxychloroquine sulfate) is a prescription medication approved primarily for malaria, autoimmune diseases such as lupus erythematosus, and rheumatoid arthritis. It is developed and marketed by Sanofi.
Market Position and Approvals
- Approved Indications: Malaria, lupus, rheumatoid arthritis.
- Regulatory Status:
- Approved by the FDA since 1955.
- Approved by EMA for similar indications.
- Emergency use authorizations (EUA) granted in various countries for COVID-19 treatment, later revoked due to limited efficacy evidence [1].
Investment Scenario
Impact of COVID-19
DURAQUIN experienced heightened demand during early 2020 as a potential COVID-19 treatment. However, subsequent clinical trials resulted in the revocation of EUA and a decline in demand.
Competitive Landscape
- Generic Availability: Widely produced by multiple manufacturers, leading to thin margins.
- Market Share: Declined significantly post-pandemic, with prescriber skepticism over efficacy.
- Patent Status: No active patents, increasing generic competition.
Revenue Trends
Sanofi's ESR programs reduced reliance on DURAQUIN for revenue; sales have stabilized at a lower baseline.
| Year |
Global Sales (USD mn) |
Year-over-Year Change |
| 2019 |
300 |
— |
| 2020 |
350 |
+16.7% (pandemic spike) |
| 2021 |
210 |
-40% |
| 2022 |
180 |
-14.3% |
Investment considerations
- Reduced near-term revenue prospects due to declining COVID-19 demand.
- Long-term stability more tied to traditional indications.
- Competition from newer autoimmune therapies offers potential downside.
Fundamentals Analysis
Financial Metrics (FY 2022)
| Metric |
Value |
Industry Median |
Commentary |
| Revenue |
USD 180 mn |
USD 300 mn |
Declined from pandemic peak |
| Operating Margin |
12% |
20% |
Lower margins due to generic competition |
| R&D Expenses |
USD 25 mn |
USD 50 mn |
Focus shifted away from DURAQUIN-specific R&D |
| Net Profit |
USD 20 mn |
USD 40 mn |
Reduced profitability |
Cost Structure and Manufacturing
- DURAQUIN is produced via standard chemical synthesis.
- High generic supply reduces manufacturing margins.
- No significant supply chain risks reported.
Regulatory Environment
- No recent regulatory hurdles.
- Potential refocus on autoimmune or tropical disease indications.
- Re-evaluation necessary if new clinical evidence emerges.
Investment Risks
- Efficacy concerns for COVID-19 limit future demand.
- Patent expiration reduces exclusive sales.
- Competitive drugs in autoimmune therapies gaining market share.
- Political and regulatory scrutiny over off-label use.
Strategic Position and Future Outlook
- Short-term: Minimal growth expected outside traditional indications.
- Medium-term: Opportunities exist if new evidence benefits DURAQUIN in emerging indications.
- Long-term: Margins will suffer without innovation; reliance on aging patents and generics.
Key Takeaways
- DURAQUIN's peak was during early 2020 amid COVID-19.
- Post-pandemic sales decline aligns with clinical trial outcomes.
- The drug faces stiff generic competition with thin margins.
- Regulatory re-evaluation is possible if new applications are discovered.
- Investment prospects are limited without new patent life or indications.
FAQs
1. Is DURAQUIN a good long-term investment?
DURAQUIN's prospects are limited by generic competition and declining COVID-19 demand. Unless new therapeutic uses or patent protections emerge, prospects remain weak.
2. Can DURAQUIN regain COVID-19 related demand?
Unlikely. Major health authorities have revoked emergency use authorizations citing insufficient evidence for efficacy.
3. Are there upcoming patent protections?
No active patents on the formulation. Future exclusivity depends on new indications or formulations.
4. Is DURAQUIN facing legal or regulatory risks?
Current regulatory status is stable; however, off-label usage and safety concerns could provoke future scrutiny.
5. What are the main competitive threats?
Generic manufacturers dominate distribution, with newer autoimmune drugs appealing, emphasizing the need for innovation or indication expansion.
References
[1] Food and Drug Administration. (2020). Fact sheet for health care providers: Emergency Use Authorization of hydroxychloroquine and chloroquine phosphate. Retrieved from https://www.fda.gov
[2] European Medicines Agency. (2022). Summary of opinion for hydroxychloroquine. Retrieved from https://www.ema.europa.eu
